Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A

This phase 3 pivotal study evaluated the safety, efficacy, and pharmacokinetics of a recombinant FVIII Fc fusion protein (rFVIIIFc) for prophylaxis, treatment of acute bleeding, and perioperative hemostatic control in 165 previously treated males aged ≥12 years with severe hemophilia A. The study ha...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Mahlangu, Johnny, Powell, Jerry S., Ragni, Margaret V., Chowdary, Pratima, Josephson, Neil C., Pabinger, Ingrid, Hanabusa, Hideji, Gupta, Naresh, Kulkarni, Roshni, Fogarty, Patrick, Perry, David, Shapiro, Amy, Pasi, K. John, Apte, Shashikant, Nestorov, Ivan, Jiang, Haiyan, Li, Shuanglian, Neelakantan, Srividya, Cristiano, Lynda M., Goyal, Jaya, Sommer, Jurg M., Dumont, Jennifer A., Dodd, Nigel, Nugent, Karen, Vigliani, Gloria, Luk, Alvin, Brennan, Aoife, Pierce, Glenn F.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2014
Assuntos:
Plenary Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3894491/
https://ncbi.nlm.nih.gov/pubmed/24227821
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-10-529974
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados